This will be a one-time survey. The burden estimate is based on FDA's experience with the 1992–1993 survey mentioned in the previous paragraph.

Dated: March 20, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–7604 Filed 3–25–97; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 97N–0007]

Land O'Lakes, Inc., et al.; Withdrawal of Approval of NADA's

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of two new animal drug applications (NADA's) held by Land O' Lakes, Inc., and three NADA's held by ADM Animal Health & Nutrition Div. The sponsors requested voluntary withdrawal of approval of the NADA's. In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the regulations by removing those portions which reflect approval of these NADA's.

EFFECTIVE DATE: April 4, 1997.

FOR FURTHER INFORMATION CONTACT: Mohammad I. Sharar, Center for Veterinary Medicine (HFV–216), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0159.

SUPPLEMENTARY INFORMATION: Land O'Lakes, Inc., Agricultural Services, 2827 Eighth Avenue South, Fort Dodge, IA 50501, has requested withdrawal of approval of NADA 42–489 tylosin Type A medicated articles and NADA 98–156 tylosin/sulfamethazine Type A medicated articles.

ADM Animal Health & Nutrition Div., P.O. Box 2508, Fort Wayne, IN 46801–2508, has requested withdrawal of approval of NADA 118–874 pyrantel tartrate Type A medicated articles (the NADA originally held by Henwood Feed Additives, Inc.), NADA 127–825 hygromycin B Type A medicated articles and NADA 127–826 tylosin/sulfamethazine Type A medicated articles (the NADA's originally held by Music City Supplement Co.).

The sponsors requested withdrawal of approval of the NADA's.

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with 21 CFR 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADA's 42–489, 98–156, 118–874, 127–825, and 127–826 and all supplements and amendments thereto is hereby withdrawn, effective April 4, 1997.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending 21 CFR 510.600, 558.274, 558.485, 558.625, and 558.630 to reflect withdrawal of approval of these NADA's.

Dated: March 13, 1997.

Michael J. Blackwell,

Deputy Director, Center for Veterinary Medicine.

[FR Doc. 97–7540 Filed 3–25–97; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETING: The following advisory committee meeting is announced:

Transmissible Spongiform Encephalopathies Advisory Committee

Date, time, and place. April 23, 1997, 9 a.m., and April 24, 1997, 8 a.m., Holiday Inn—Bethesda, Versailles Ballrooms III and IV, 8120 Wisconsin Ave., Bethesda, MD.

Type of meeting and contact person. Open public hearing, April 23, 1997, 9 a.m. to 10 a.m., unless public participation does not last that long; open committee discussion, 10 a.m. to 5 p.m.; closed committee deliberations, 5 p.m. to 6 p.m.; open committee discussion, April 24, 1997, 8 a.m. to 5 p.m.; William Freas or Jane S. Brown, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–594–6700, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Transmissible Spongiform Encephalopathies Advisory Committee, code 12388. Please call the hotline for information concerning any possible changes.

General function of the committee. The committee reviews and evaluates available scientific data concerning the safety of products which may be at risk for transmission of spongiform encephalopathies having an impact on the public health.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before April 18, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss and provide recommendations on the safety of both domestic and imported gelatin and gelatin byproducts with regard to the risk imposed by bovine spongiform encephalopathy.

Closed committee deliberations. On April 23, 1997, the committee will review trade secret and/or confidential commercial information relevant to current and pending products. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C 552b(c)(4)).

Each public advisory committee meeting listed above may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. The dates and times reserved